retatrutide trial weight loss Retatrutide: Phase 3 Results (Up to 28.7% Loss), Mechanism, Trials & 2026 Updates Retatrutide Online | Simple Online

But, McIntyre cautions, despite these encouraging preliminary results, these medications are not proven psychiatric treatments, and they are not ready for prime time

However, resting metabolic rate, adjusted for lean body mass, did not differ between treatments

Retatrutide (development code LY-3437943) is a synthetic peptide developed by Eli Lilly and Company designed to act simultaneously on three hormone-receptor pathways: GLP-1 (glucagonlike peptide-1) GIP (glucosedependent insulinotropic polypeptide) Glucagon receptor (GCG) nejm.org Put simply: it takes the mechanism of todays weight-loss injections and adds an extra dimension of hormonal stimulation, with the aim of significantly greater weight-loss outcomes

2024;7(1) doi: 10.1001/jamanetworkopen.2023.52824